Read this topic

Agomelatine mechanism matters because it is an antidepressant that works through the body's circadian (daily) rhythm system rather than through the monoamine reuptake mechanisms most antidepressants share, and that different route brings a different side-effect trade-off. It acts as an agonistA drug or chemical that activates a receptor to produce an effect.Read more → (a drug that activates a receptor) at melatonin receptors MT1 and MT2, resynchronising disrupted sleep-wake timing, and as an antagonistA drug that blocks a receptor, stopping it from being activated.Read more → at 5-HT2C (a serotonin receptor subtype) receptors. For example, imagine a depressed patient whose sleep pattern is badly disrupted, going to bed very late and waking exhausted: agomelatine's action on the circadian system directly targets this pattern in a way an SSRISelective serotonin reuptake inhibitor, a common type of antidepressant.Read more → (selective serotonin reuptake inhibitor) does not. In practice, this dual mechanism is why agomelatine causes less sexual dysfunction and fewer discontinuation symptoms than SSRIs.

Agomelatine's MT1/MT2 melatonin receptor agonism resets circadian timing, while its 5-HT2C antagonism contributes an antidepressant and anxiolyticA drug that reduces anxiety.Read more → (anxiety-reducing) effect without the serotonin reuptake blockade responsible for SSRISelective serotonin reuptake inhibitor, a common type of antidepressant.Read more → sexual side effects. Because it does not act on the serotonin transporter directly, agomelatine causes less sexual dysfunction and a milder discontinuation syndromeWithdrawal-like symptoms that follow suddenly stopping a drug such as an antidepressant.Read more → than SSRIs when stopped. The key safety issue is hepatotoxicity (liver damage): liver function tests (LFTsLiver function tests, a blood test that checks how well the liver is working.Read more →) must be checked before starting, then periodically during treatment, particularly in the first months and with dose increases. For example, imagine a patient started on agomelatine whose baseline LFTs are not checked: emerging hepatotoxicity could go unnoticed until it is advanced. In practice, this means agomelatine is avoided or used with particular caution in patients with pre-existing liver impairment, and never combined with fluvoxamine, a potent CYP1A2 inhibitor that raises agomelatine levels.

• A man with depression and established cirrhosis is being considered for agomelatine. What is the correct position on prescribing this drug for him?
• A woman is started on agomelatine and asks how often her blood tests will be repeated. Which schedule best reflects standard recommended monitoring?
• Besides acting at melatonin receptors, agomelatine blocks a serotonin receptor subtype. What is the downstream consequence of that blockade in the frontal cortex?
• A woman stopping agomelatine after several months asks whether she should taper it. Which feature of this drug is relevant to that question?

• Agomelatine, MT1/MT2 melatonin agonism plus 5-HT2C antagonism with hepatotoxicity risk, unlike SSRIs, which block serotonin reuptake and carry sexual dysfunction and discontinuation risk instead.
• Melatonin (over-the-counter), a direct MT1/MT2 agonistA drug or chemical that activates a receptor to produce an effect.Read more → without 5-HT2C antagonism or hepatotoxicity monitoring requirements, rather than agomelatine's dual mechanism and liver safety profile.
• Mirtazapine, works via alpha-2 antagonism and 5-HT2/5-HT3 blockade causing sedation and weight gain, whereas agomelatine is comparatively weight-neutral and non-sedating in the same way.
• Fluvoxamine co-prescription, a potent CYP1A2 inhibitor that dangerously raises agomelatine levels, unlike most other antidepressants which do not interact this strongly with agomelatine's metabolism.

• Liver disease makes this drug less rather than more suitable.
• Dose reduction does not make the drug safe in established liver disease.
• Liver disease materially changes the safety of this particular drug.
• A single baseline test would miss later-emerging liver injury.
• Yearly testing is far too infrequent for this drug's risk profile.

• Identify the drug, receptor, enzyme or pharmacokinetic change named in the stem.
• Translate it into the immediate mechanism before looking at the options.
• Use timing and the adverse-effect pattern to separate the nearest alternatives.
• Check whether the question asks for mechanism, clinical consequence, monitoring or management.